{
    "info": {
        "nct_id": "NCT05786924",
        "official_title": "A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms",
        "inclusion_criteria": "1. Disease criteria:\n\n   1. Histologically or cytologically confirmed recurrent/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations.\n\n      Note: Patients may have stable central nervous system (CNS) metastases. Patients with active CNS metastases or primary CNS tumors associated with progressive neurological symptoms or needing increased doses of corticosteroids to control the CNS disease are excluded from the study.\n   2. Dose Escalation cohorts:\n\n      * NSCLC with KRAS non-G12C mutations, including other mutations at KRAS-G12 (eg, G12V/G12D) and other oncogenic variants of KRAS mutations on G13 and Q61 amino acid residues, BRAF, or CRAF mutations.\n      * Melanoma with BRAF, CRAF, or NRAS mutations.\n      * Histiocytic neoplasms with BRAF or NRAS mutations.\n      * Thyroid carcinoma with BRAF mutations.\n      * Colorectal carcinoma with BRAF (Class II or III) mutations with Sponsor approval.\n      * Other solid tumors with BRAF Class I mutations after prior treatment with a BRAF/MEK inhibitor or local standard-of-care with Sponsor approval.\n   3. Dose Expansion cohort:\n\n   Recurrent advanced/metastatic NSCLC with KRAS non-G12C mutations without small cell lung cancer transformation with progressive disease confirmed by radiographic assessment.\n2. Prior standard-of-care\n\n   For dose levels <200 mg once daily and/or not at preliminary RP2D(s):\n   1. Exhausted all available standard-of-care therapies or, in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from available standard-of-care therapy.\n   2. Patients with eligible tumors harboring BRAF V600E mutations must have received FDA approved BRAF targeted therapy, BRAF/MEK inhibitors combination, or BRAF inhibitors combination.\n\n   For dose levels â‰¥200 mg once daily or at preliminary RP2D(s):\n\n   a. Patients must have received at least 1 but no more than 2 prior lines of systemic therapy for metastatic/advanced disease (adjuvant and maintenance therapy do not count towards the limit).\n3. Evaluable or measurable disease in dose escalation and measurable disease only for dose expansion cohorts.\n4. Adequate bone marrow and organ function.\n5. Recovered from toxicity to prior anti-cancer therapy.\n6. Appropriate candidate for BDTX-4933 monotherapy.\n7. Life expectancy of >=12 weeks in the opinion of the Investigator.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Cancer that has a known MEK1/2 mutation.\n2. Major surgery within 4 weeks of study entry or planned during study.\n3. Ongoing anticancer therapy.\n4. Ongoing radiation therapy.\n5. Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.\n6. Symptomatic spinal cord compression.\n7. Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.\n8. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.\n9. Females who are pregnant or breastfeeding.\n10. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\n11. Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Colorectal carcinoma with BRAF (Class II or III) mutations with Sponsor approval.",
            "criterions": [
                {
                    "exact_snippets": "Colorectal carcinoma",
                    "criterion": "colorectal carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "BRAF (Class II or III) mutations",
                    "criterion": "BRAF mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation class",
                            "expected_value": [
                                "Class II",
                                "Class III"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with Sponsor approval",
                    "criterion": "sponsor approval",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically or cytologically confirmed recurrent/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "recurrent/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms",
                    "criterion": "disease type/status",
                    "requirements": [
                        {
                            "requirement_type": "disease_type",
                            "expected_value": [
                                "solid tumor",
                                "histiocytic neoplasm"
                            ]
                        },
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "recurrent",
                                "advanced (unresectable)",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with documented RAS or BRAF mutations",
                    "criterion": "RAS or BRAF mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation_status",
                            "expected_value": "documented RAS or BRAF mutation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Dose Expansion cohort:",
            "criterions": [
                {
                    "exact_snippets": "Dose Expansion cohort",
                    "criterion": "cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort type",
                            "expected_value": "Dose Expansion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NSCLC with KRAS non-G12C mutations, including other mutations at KRAS-G12 (eg, G12V/G12D) and other oncogenic variants of KRAS mutations on G13 and Q61 amino acid residues, BRAF, or CRAF mutations.",
            "criterions": [
                {
                    "exact_snippets": "NSCLC",
                    "criterion": "non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "KRAS non-G12C mutations",
                    "criterion": "KRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation subtype",
                            "expected_value": "non-G12C"
                        }
                    ]
                },
                {
                    "exact_snippets": "other mutations at KRAS-G12 (eg, G12V/G12D)",
                    "criterion": "KRAS-G12 mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation subtype",
                            "expected_value": [
                                "G12V",
                                "G12D",
                                "other G12"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "other oncogenic variants of KRAS mutations on G13 and Q61 amino acid residues",
                    "criterion": "KRAS mutation at G13 or Q61",
                    "requirements": [
                        {
                            "requirement_type": "mutation site",
                            "expected_value": [
                                "G13",
                                "Q61"
                            ]
                        },
                        {
                            "requirement_type": "oncogenic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "BRAF ... mutations",
                    "criterion": "BRAF mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CRAF mutations",
                    "criterion": "CRAF mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Appropriate candidate for BDTX-4933 monotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Appropriate candidate for BDTX-4933 monotherapy",
                    "criterion": "candidate suitability for BDTX-4933 monotherapy",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Life expectancy of >=12 weeks in the opinion of the Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of >=12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator",
                    "criterion": "investigator opinion of life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Melanoma with BRAF, CRAF, or NRAS mutations.",
            "criterions": [
                {
                    "exact_snippets": "Melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "BRAF, CRAF, or NRAS mutations",
                    "criterion": "BRAF, CRAF, or NRAS mutations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Exhausted all available standard-of-care therapies or, in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from available standard-of-care therapy.",
            "criterions": [
                {
                    "exact_snippets": "Exhausted all available standard-of-care therapies",
                    "criterion": "standard-of-care therapies",
                    "requirements": [
                        {
                            "requirement_type": "exhaustion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator, would be unlikely to tolerate ... available standard-of-care therapy",
                    "criterion": "tolerability of standard-of-care therapy",
                    "requirements": [
                        {
                            "requirement_type": "tolerability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator, would be unlikely to ... derive clinically meaningful benefit from available standard-of-care therapy",
                    "criterion": "benefit from standard-of-care therapy",
                    "requirements": [
                        {
                            "requirement_type": "clinically meaningful benefit",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histiocytic neoplasms with BRAF or NRAS mutations.",
            "criterions": [
                {
                    "exact_snippets": "Histiocytic neoplasms",
                    "criterion": "histiocytic neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "BRAF or NRAS mutations",
                    "criterion": "BRAF or NRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior standard-of-care",
            "criterions": [
                {
                    "exact_snippets": "Prior standard-of-care",
                    "criterion": "prior standard-of-care",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other solid tumors with BRAF Class I mutations after prior treatment with a BRAF/MEK inhibitor or local standard-of-care with Sponsor approval.",
            "criterions": [
                {
                    "exact_snippets": "Other solid tumors with BRAF Class I mutations",
                    "criterion": "solid tumor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "solid tumor"
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "not primary tumor of interest (i.e., 'other' solid tumors)"
                        }
                    ]
                },
                {
                    "exact_snippets": "BRAF Class I mutations",
                    "criterion": "BRAF mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation class",
                            "expected_value": "Class I"
                        }
                    ]
                },
                {
                    "exact_snippets": "after prior treatment with a BRAF/MEK inhibitor or local standard-of-care",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "BRAF/MEK inhibitor",
                                "local standard-of-care"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with Sponsor approval",
                    "criterion": "sponsor approval",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Dose Escalation cohorts:",
            "criterions": [
                {
                    "exact_snippets": "Dose Escalation cohorts",
                    "criterion": "cohort assignment",
                    "requirements": [
                        {
                            "requirement_type": "cohort type",
                            "expected_value": "Dose Escalation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Disease criteria:",
            "criterions": [
                {
                    "exact_snippets": "Disease criteria",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "meets disease criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "For dose levels â‰¥200 mg once daily or at preliminary RP2D(s):",
            "criterions": [
                {
                    "exact_snippets": "dose levels â‰¥200 mg once daily",
                    "criterion": "dose level",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "once daily"
                        }
                    ]
                },
                {
                    "exact_snippets": "preliminary RP2D(s)",
                    "criterion": "dose level",
                    "requirements": [
                        {
                            "requirement_type": "RP2D status",
                            "expected_value": "preliminary RP2D"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "For dose levels <200 mg once daily and/or not at preliminary RP2D(s):",
            "criterions": [
                {
                    "exact_snippets": "dose levels <200 mg once daily",
                    "criterion": "dose level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 200,
                                "unit": "mg once daily"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not at preliminary RP2D(s)",
                    "criterion": "dose level",
                    "requirements": [
                        {
                            "requirement_type": "preliminary RP2D status",
                            "expected_value": "not at preliminary RP2D"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with eligible tumors harboring BRAF V600E mutations must have received FDA approved BRAF targeted therapy, BRAF/MEK inhibitors combination, or BRAF inhibitors combination.",
            "criterions": [
                {
                    "exact_snippets": "eligible tumors harboring BRAF V600E mutations",
                    "criterion": "tumor BRAF V600E mutation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have received FDA approved BRAF targeted therapy, BRAF/MEK inhibitors combination, or BRAF inhibitors combination",
                    "criterion": "prior BRAF-targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "FDA approved BRAF targeted therapy",
                                "BRAF/MEK inhibitors combination",
                                "BRAF inhibitors combination"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. Patients must have received at least 1 but no more than 2 prior lines of systemic therapy for metastatic/advanced disease (adjuvant and maintenance therapy do not count towards the limit).",
            "criterions": [
                {
                    "exact_snippets": "received at least 1 but no more than 2 prior lines of systemic therapy for metastatic/advanced disease",
                    "criterion": "number of prior lines of systemic therapy for metastatic/advanced disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adjuvant and maintenance therapy do not count towards the limit",
                    "criterion": "adjuvant and maintenance therapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from prior lines count",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Evaluable or measurable disease in dose escalation and measurable disease only for dose expansion cohorts.",
            "criterions": [
                {
                    "exact_snippets": "Evaluable or measurable disease in dose escalation",
                    "criterion": "disease status in dose escalation cohort",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "evaluable",
                                "measurable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease only for dose expansion cohorts",
                    "criterion": "disease status in dose expansion cohort",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "measurable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Recovered from toxicity to prior anti-cancer therapy.",
            "criterions": [
                {
                    "exact_snippets": "Recovered from toxicity to prior anti-cancer therapy.",
                    "criterion": "toxicity to prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "recovered"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Patients may have stable central nervous system (CNS) metastases. Patients with active CNS metastases or primary CNS tumors associated with progressive neurological symptoms or needing increased doses of corticosteroids to control the CNS disease are excluded from the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients may have stable central nervous system (CNS) metastases.",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with active CNS metastases ... are excluded from the study.",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "primary CNS tumors associated with progressive neurological symptoms ... are excluded from the study.",
                    "criterion": "primary CNS tumors",
                    "requirements": [
                        {
                            "requirement_type": "neurological symptoms",
                            "expected_value": "progressive"
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "needing increased doses of corticosteroids to control the CNS disease are excluded from the study.",
                    "criterion": "corticosteroid dose for CNS disease control",
                    "requirements": [
                        {
                            "requirement_type": "dose change",
                            "expected_value": "increased"
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Recurrent advanced/metastatic NSCLC with KRAS non-G12C mutations without small cell lung cancer transformation with progressive disease confirmed by radiographic assessment.",
            "criterions": [
                {
                    "exact_snippets": "Recurrent advanced/metastatic NSCLC",
                    "criterion": "non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "recurrent",
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "KRAS non-G12C mutations",
                    "criterion": "KRAS mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "non-G12C"
                        }
                    ]
                },
                {
                    "exact_snippets": "without small cell lung cancer transformation",
                    "criterion": "small cell lung cancer transformation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive disease confirmed by radiographic assessment",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "radiographic assessment"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Thyroid carcinoma with BRAF mutations.",
            "criterions": [
                {
                    "exact_snippets": "Thyroid carcinoma",
                    "criterion": "thyroid carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "BRAF mutations",
                    "criterion": "BRAF mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "5. Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled or active"
                        },
                        {
                            "requirement_type": "clinical relevance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled or active"
                        },
                        {
                            "requirement_type": "clinical relevance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy",
                    "criterion": "specific viral infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled or active"
                        },
                        {
                            "requirement_type": "clinical relevance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Symptomatic spinal cord compression.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic spinal cord compression",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Females who are pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Females who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Females who are ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.",
                    "criterion": "active malignancy (other than study-specific malignancies)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "need for systemic therapy within the next 2 years",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Ongoing anticancer therapy.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing anticancer therapy",
                    "criterion": "anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.",
            "criterions": [
                {
                    "exact_snippets": "Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway",
                    "criterion": "prior use of experimental agents targeting KRAS/BRAF/MEK/ERK pathway",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Ongoing radiation therapy.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing radiation therapy",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.",
            "criterions": [
                {
                    "exact_snippets": "History or current evidence of retinal vein occlusion (RVO)",
                    "criterion": "retinal vein occlusion (RVO)",
                    "requirements": [
                        {
                            "requirement_type": "history or current evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current risk factors for RVO",
                    "criterion": "risk factors for retinal vein occlusion (RVO)",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Major surgery within 4 weeks of study entry or planned during study.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of study entry",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "planned during study",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned during study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Cancer that has a known MEK1/2 mutation.",
            "criterions": [
                {
                    "exact_snippets": "Cancer that has a known MEK1/2 mutation",
                    "criterion": "cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known MEK1/2 mutation",
                    "criterion": "MEK1/2 mutation",
                    "requirements": [
                        {
                            "requirement_type": "known mutation status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.",
            "criterions": [
                {
                    "exact_snippets": "Actively receiving systemic treatment ... on another therapeutic clinical study",
                    "criterion": "systemic treatment on another therapeutic clinical study",
                    "requirements": [
                        {
                            "requirement_type": "current status",
                            "expected_value": "actively receiving"
                        }
                    ]
                },
                {
                    "exact_snippets": "Actively receiving ... direct medical intervention on another therapeutic clinical study",
                    "criterion": "direct medical intervention on another therapeutic clinical study",
                    "requirements": [
                        {
                            "requirement_type": "current status",
                            "expected_value": "actively receiving"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "Key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [
        {
            "line": "4. Adequate bone marrow and organ function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}